{"id":"NCT00485758","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2007-06-13","resultsPosted":"2009-09-11","lastUpdate":"2015-10-12"},"enrollment":796,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus Type 2"],"interventions":[{"type":"DRUG","name":"ER niacin/laropiprant","otherNames":["MK0524A","CORDAPTIVEâ„¢","laropiprant (+) niacin"]},{"type":"DRUG","name":"Comparator : placebo (unspecified)","otherNames":[]}],"arms":[{"label":"1","type":"OTHER"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.","primaryOutcome":{"measure":"Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo","timeFrame":"Baseline and 12 Weeks","effectByArm":[{"arm":"Extended Release Niacin/Laropiprant","deltaMin":-15.8,"sd":null},{"arm":"Placebo","deltaMin":2.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25750540","22500948","22400810","21401833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":449},"commonTop":["Flushing","Pruritus","Blood glucose increased","Diarrhoea","Nasopharyngitis"]}}